logo
Sign in

CLCS Stock Price, Chart, Stats & News

Cell Source, Inc.
Save

Cell Source, Inc. (CLCS) does not currently pay a dividend.

31.39M
Market cap
–
Current P/E
–
Forward P/E

CLCS chart

About

Health care
Sector
Biotechnology
Industry

Cell Source, Inc. is a biotechnology firm dedicated to creating cell-based therapies centered on regulating immune tolerance. The company's flagship innovation is its Veto Cell immune system management technology, an advanced immune tolerance platform capable of selectively suppressing specific immune responses. This Veto Cell technology finds application in numerous areas, including enhancing the acceptance of stem cell transplants for conditions like lymphoma, leukemia, and multiple myeloma.

Similar securities

Based on sector and market capitalization

Report issue